The Tat protein of human immunodeficiency virus type 1 is a potent transcriptional trans activator of the viral long terminal repeat promoter element. Tat function requires the direct interaction of Tat with a cis-acting viral RNA target sequence termed the trans-activation response (TAR) element and has also been proposed to require at least one cellular cofactor. We have used a genetic approach to attempt to experimentally define the role of the cellular cofactor in Tat function and TAR binding. Our data suggest that neither Tat nor the cellular cofactor binds to TAR alone in vivo and indicate, instead, that the interaction of Tat with its cellular cofactor is a prerequisite for TAR binding. The known species tropism of lentivirus Tat proteins appears to arise from the fact that not only Tat but also the cellular cofactor can markedly influence the RNA sequence specificity of the resultant protein complex. These data also suggest that the Tat cofactor is likely a cellular transcription factor that has been highly conserved during vertebrate evolution. We hypothesize that the primary function of Tat is to redirect this cellular factor to a novel viral RNA target site and to thereby induce activation of viral gene expression.
The Tat protein of human immunodeficiency virus type 1 is a potent transcriptional trans activator of the viral long terminal repeat promoter element. Tat function requires the direct interaction of Tat with a cis-acting viral RNA target sequence termed the trans-activation response (TAR) element and has also been proposed to require at least one cellular cofactor. We have used a genetic approach to attempt to experimentally define the role of the cellular cofactor in Tat function and TAR binding. Our data suggest that neither Tat nor the cellular cofactor binds to TAR alone in vivo and indicate, instead, that the interaction of Tat with its cellular cofactor is a prerequisite for TAR binding. The known species tropism of lentivirus Tat proteins appears to arise from the fact that not only Tat but also the cellular cofactor can markedly influence the RNA sequence specificity of the resultant protein complex. These data also suggest that the Tat cofactor is likely a cellular transcription factor that has been highly conserved during vertebrate evolution. We hypothesize that the primary function of Tat is to redirect this cellular factor to a novel viral RNA target site and to thereby induce activation of viral gene expression.
Replication of the pathogenic retrovirus human immunodeficiency virus type 1 (HIV-1) is critically dependent on the functional expression of the viral nuclear regulatory proteins Tat and Rev (reviewed in reference 12). The Tat protein is a transcriptional trans activator of the HIV-1 long terminal repeat (LTR) promoter element, while Rev acts posttranscriptionally to induce the cytoplasmic expression of mRNAs that encode the viral structural proteins. The mechanisms of action of Tat and Rev, while therefore clearly distinct, are nevertheless each dependent on their direct interaction with cis-acting viral RNA target sites termed, respectively, the trans-activation response (TAR) element (14, 40, 49) and the Rev response element (RRE) (29, 51) .
Although many DNA and RNA tumor viruses encode sequence-specific transcriptional trans activators, the HIV-1 Tat protein is highly unusual in acting via an RNA, rather than a DNA, target sequence. Indeed, similar RNA sequence-specific regulatory proteins have as yet been observed only in the other primate immunodeficiency viruses and in a subset of the more distantly related ungulate lentiviruses, including equine infectious anemia virus (EIAV) and bovine immunodeficiency virus (12, 13, 27) . While the precise mechanism of action of these lentivirus Tat proteins has remained uncertain, activation of viral RNA expression at both the level of transcription initiation and the level of elongation has been proposed (15, 19, 23, 24, 26, 31, 
44).
Many eukaryotic transcription factors display a modular domain structure featuring discrete protein sequences involved, respectively, in conferring nucleic acid sequence specificity and in activating transcription from the bound template (32, 37) . Similarly, mutational analysis has led to the definition of two domains within the 86-amino-acid Tat protein that appear to fulfill comparable functions (Fig. 1) . The arginine-rich basic domain of Tat not only acts as a nuclear localization signal (41) but also is both necessary and * Corresponding author.
fully sufficient for specific binding to TAR in vitro (6, 40, 49) . The core motif of Tat is highly conserved among all lentiviral Tat proteins, while the cysteine motif is conserved in all primate lentiviruses (8) . Mutation of either of these two motifs can inactivate HIV-1 Tat function in vivo without affecting the ability of the protein to bind TAR in vitro (17, 22, 41, 47) . These sequences have therefore been proposed to form a cellular cofactor binding domain (8, 9, 13, 42, 47) . While less well conserved sequences located N terminal to these Tat motifs are essential for full biological activity in vivo, the more C-terminal sequences, including the second coding exon of Tat, appear dispensable for efficient trans activation of the HIV-1 LTR (8, 13, 17, 25, 39, 44, 47) (Fig.  1) .
The cis-acting RNA target site for HIV-1 Tat is a 59-nucleotide (nt) RNA stem-loop structure located immediately proximal to the start site for viral mRNA transcription ( Fig. 2) (4, 16) . Mutations that disrupt the helical structure of the 27-nt apical region of TAR, or that affect the pyrimidinerich 3-nt bulge, prevent TAR function in vivo and also inhibit the in vitro interaction of Tat with TAR (3, 14, 40) . In contrast, mutation of the 6-nt terminal loop of TAR has no detectable affect on the in vitro Tat-TAR interaction yet effectively blocks TAR function in vivo (14, 16) . It has therefore been proposed that trans activation of the HIV-1 LTR by Tat might require the specific interaction of not only Tat but also a cellular cofactor(s) with TAR (40) . It has further been suggested that a specific interaction of this TAR-binding cellular cofactor(s) with Tat might well be critical to the formation of this hypothetical ternary complex (46) . Although several cellular proteins that bind to TAR or Tat have been reported, the identification of a cellular cofactor required for Tat function and the definition of the role of this cofactor in the mechanism of action of Tat have so far remained elusive (30, 34, 50) .
In this study, we have used a range of genetic approaches to address this latter question. Our data support the hypothesis that the primary role of Tat is to recruit a cellular transcription factor to the HIV-1 LTR TAR element. These (8, 13) . The core motif, marked by the consensus amino acid sequence N'-KXLGIXY-C', is conserved in all lentivirus Tat proteins. In contrast, five of the seven cysteine residues that constitute the essential Cys motif of HIV-1 Tat are lacking in the eTat protein (8) .
data further suggest that neither Tat nor the cellular cofactor is capable of interacting with TAR on its own in vivo.
MATERIALS AND METHODS
Construction of molecular clones. We have previously described the cytomegalovirus immediate-early promoterbased expression vector pBC12/CMV as well as derivatives containing cDNA forms of the HIV-1 tat gene (pcTat) and rev gene (pcRev) (48) . Expression plasmids containing the mutant AN, C22S, C37S, and K41A forms of HIV-1 Tat were derived from pcTat as previously described (41, 47) . The ARK Tat mutant contains an extensive substitution mutation within the Tat basic motif that changes Tat amino acids 50 to 56 from N'-KKRRQRR-C' to N'-YVQILLY-C'. The ARK mutation was generated in the pcTat context by using the polymerase chain reaction (33) with overlapping oligonucleotide primers encoding the appropriate amino acid changes. The expression plasmid pcTat/Rev encodes a fusion protein consisting of the full-length HIV-1 Tat protein attached to the N terminus of the full-length HIV-1 Rev protein (48) . Plasmids encoding mutant forms of Tat in this Tat-Rev fusion context were derived as previously described (48) . Reporter plasmids containing the cat indicator gene under the control of the wild-type HIV-1 LTR (pTAR/CAT) or under the control of an HIV-1 LTR containing the stem-loop IIB (SLIIB) domain of the RRE in place of TAR (pSLIIB/ CAT) have been described previously, as has the Rev function reporter plasmid pDM128/CMV (21, 28, 48) .
All EIAV expression plasmids were derived from the pMA-1 proviral clone (1) . A full-length cDNA copy of the EIAV tat gene was derived by the polymerase chain reaction, using oligonucleotide primers that permitted isolation of both coding exons of EIAV tat. The 5' primer used to isolate the first exon substituted an NcoI site and a consensus translation initiation codon (5'-CCAUGG-3') in place of the leucine codon that normally serves as the initiation codon for EIAV Tat (eTat) (8) . The 3' primer inserted an EagI site at the end of the first exon. Oligonucleotide primers used to isolate the second eTat exon inserted an EagI site at the beginning of this exon and introduced a unique XhoI site immediately 3' to the Tat translation termination codon. A cDNA generated by ligation of these two genomic EIAV tat gene fragments at the introduced EagI site encodes the Correct eTat amino acid sequence, although the codon usage for arginine 32 (AGA--CGG) and proline 33 (CCC--CCG) is modified. The resultant NcoI-to-XhoI fragment, containing the full-length EIAV tat gene, was inserted into the pBC12/ CMV expression plasmid to generate peTat. Similarly, pcRev/eTat contains this full-length eTat cDNA fused to the C terminus of the HIV-1 Rev protein. The pR43G derivative of peTat contains a mutation of arginine 43 to glycine that was introduced into the EIAV tat gene by the polymerase chain reaction. This critical arginine residue is located at the equivalent position in the Tat core consensus sequence to lysine 41 of HIV-1 Tat ( Fig. 1) (8) . The pEIAV/CAT plasmid contains EIAV LTR sequences, extending from -212 to +40 relative to the cap site, substituted in place of the HIV-1 LTR of pTAR/CAT. The pEIAV/CAT plasmid therefore contains the entire EIAV TAR element (10) .
Cell culture and DNA transfection. The cell lines COS, HeLa, L, and QC1-3 were maintained as previously described (28) . HeLa and L-cell cultures were transfected by the calcium phosphate procedure, using a total of 5.1 ,ug of DNA per 35-mm-diameter plate. COS and QC1-3 cells were transfected by using DEAE-dextran and chloroquine with a total of 500 ng of DNA per 35-mm-diameter plate (11) . For assays of trans dominance, HeLa cells were transfected with 2 ,ug of the relevant chloramphenicol acetyltransferase (CAT) reporter plasmid, 0.1 ,ug of the effector plasmid, 2.0 ,ug of the competitor plasmid, and 1 ,ug of salmon sperm carrier DNA. At -48 h after transfection, cultures were harvested and relative levels of CAT enzyme activity were determined by the diffusion method (35) . All values reported were obtained during the linear phase of this kinetic assay for CAT activity and have been adjusted for any minor variability in the level of total protein in each extract, as determined by the method of Bradford (5) . Expression of the various Tat mutants in transfected COS cells was monitored by radiolabeling with [35S]cysteine followed by immunoprecipitation with a rabbit polyclonal anti-Tat antiserum as previously described (11, 47, 48) .
RESULTS
Many eukaryotic transcription factors contain discrete functional domains that confer nucleic acid sequence specificity or transcription activation potential (32, 37 (42, 43, 48 (11, 47) . At 48 h after transfection, cells were labeled with [35S]cysteine (11) , and the resultant extract was subjected to immunoprecipitation with a rabbit polyclonal anti-Tat antiserum (11, 47 To examine this issue, we introduced five distinct, wellcharacterized mutations into the Tat-Rev fusion protein context ( Fig. 1) (25, 41, 47) . In the AN mutation, Tat amino acids 2 to 9 inclusively have been deleted. The cysteine 22-to-serine (C22S) mutation is in the Tat cysteine motif, the cysteine 37-to-serine (C37S) mutation is at the border of the Tat core motif, and the lysine 41-to-alanine (K41A) mutation lies within the core motif. A fourth missense mutation, termed ARK, introduces six missense mutations into the Tat basic domain (50-KKRRQRR-56 changed to 50-YVQILLY-56). The AN deletion mutant of Tat has been reported to retain a low level of Tat activity (47) , while the four Tat missense mutations have been reported to be entirely inactive (25, 41, 47) . With the exception of the ARK mutant, which lacks a functional nuclear localization signal, these Tat mutants are predicted to show the nuclear/nucleolar subcellular localization characteristic of Tat (25, 41, 47) . To confirm that these mutations also do not significantly effect the level of synthesis and expression of Tat, we determined the level of expression of these mutant proteins in transfected tissue culture cells by using immunoprecipitation analysis (11, 47, 48) . As predicted from earlier work (25, 41, 47) , these mutations were shown to have no detectable effect on the level of Tat protein expression (Fig. 3) .
As expected, analysis of the biological activity of these fusion proteins in transfected HeLa cells demonstrated that all four Tat missense mutations abrogated the ability of the Tat-Rev fusion protein to activate expression of an indicator gene linked to the wild-type HIV-1 LTR, while the AN/Rev deletion mutant retained a minimal level of activity (Fig. 4) . Similarly, the three mutations introduced into the cysteine and core motifs of Tat also abolished the ability of the (Fig. 4) . In marked contrast, the ARK/Rev mutant remained fully active on this heterologous RNA target site.
The pDM128/CMV indicator construct contains the cat indicator gene within an RRE-containing intron and is unable to express significant levels of cytoplasmic cat mRNA in the absence of HIV-1 Rev function (21, 28) . Both Rev and the Tat-Rev fusion protein efficiently activate CAT expression from the pDM128/CMV construct upon cotransfection into HeLa cells (Fig. 4) . Similarly, all five mutant Tat-Rev fusion proteins retained the ability to induce cat gene expression from this Rev indicator construct (Fig. 4) . We therefore conclude that all of these fusion proteins are fully capable of functionally interacting with the RRE element present on the DM128/CMV-encoded cat transcript. The inability of the C22S, C37S, and K41A and AN fusion proteins to effectively activate HIV-1 LTR gene expression via the RRE-derived SLIIB RNA target therefore does not result from instability or from an inability to bind the RRE.
The Tat RNA binding domain is not autonomous in vivo.
The data presented in Fig. 4 (Fig. 1) , also retains the ability to inhibit Tat-Rev function via the SLIIB target ( (9) have also proposed a model in which Tat conveys a cellular cofactor to the TAR element, the presented model differs in that the cellular cofactor is predicted to be essential for TAR binding by Tat. inhibit Tat function via the wild-type TAR element (Table 1) . It is therefore apparent that the C22S, C37S, and K41A proteins, despite an apparently intact TAR binding motif, are nevertheless incapable of competing with Tat for binding to TAR. Of interest, the ARK mutant also exhibited a significantly reduced ability to squelch trans activation of the wild-type HIV-1 LTR by Tat compared with its ability to inhibit Tat-Rev function via the SLIIB RNA target. While this may suggest that the interaction of Tat with its cellular cofactor is stabilized by binding to the viral TAR element, the data presented in Table 1 also clearly demonstrate that the interaction of Tat with a limiting cellular cofactor can readily occur in the absence of binding to TAR. In addition, these observations argue that mutant Tat proteins that are unable to bind this cellular cofactor are also unable to effectively compete for binding to TAR regardless of whether they retain a fully intact basic domain. The simplest interpretation of these data is that the interaction of Tat with a cellular cofactor precedes, and is a prerequisite for, binding to TAR in vivo. A model for the in vivo Tat-TAR interaction that incorporates this prediction is presented in Fig. 5 .
Tat species specificity results from inefficient binding to TAR. Several groups have demonstrated that Tat is only minimally active in murine cells and have further shown that this low activity can be complemented in hybrid mouse cells containing human chromosome 12 (2, 18, 36) . Indeed, these data provide one of the strongest arguments for the importance of a human cellular cofactor in the mechanism of action of HIV-1 Tat. If the model for the temporal assembly of the Tat activation complex proposed in Fig. 5 To examine this issue, we introduced appropriate HIV-1-based indicator and effector plasmids into human HeLa cells, into mouse L cells, and into the quail cell line QC1-3. As shown in Table 2 , part A, these data reproduce the previous observation that neither Tat nor Tat-Rev can effectively trans activate the wild-type HIV-1 LTR in cells derived from these other species. In contrast, Tat-Rev was observed to be a very effective trans activator of the HIV-1 LTR via the introduced SLIIB RNA target in both murine and avian cells. We therefore conclude that it is the interaction of Tat with TAR, rather than the recruitment by Tat of an appropriate cellular cofactor, that is inefficient in these nonhuman cell lines.
Although RNA sequence-specific trans activation of transcription was first described for HIV-1, comparable regulatory proteins have subsequently been described in other primate lentiviruses and in the ungulate lentiviruses EIAV and bovine immunodeficiency virus (8, 13, 27) . The eTat protein has been extensively studied by Derse and coworkers and has a number of interesting properties. EIAV TAR, like HIV-1 TAR, has been shown to form an RNA stem-loop structure (10) . However, EIAV TAR lacks both the bulge and the loop sequences that are known to be critical for HIV-1 TAR function (Fig. 2) . Further, while eTat contains sequences that are similar to the HIV-1 Tat basic and core motifs, it lacks any equivalent of the equally critical cysteine motif ( Fig. 1) (pcRev/eTat). In addition, we constructed an indicator plasmid, termed pEIAV/CAT, that placed the cat gene under the control of EIAV LTR sequences previously shown to be fully responsive to eTat (10) . Analysis of these constructs in transfected HeLa cells confirmed the modest activity of eTat in human cells (Table 2 , part B). However, the Rev-eTat fusion protein proved as effective as the HIV-1 Tat-Rev fusion protein in activating the HIV-1 LTR via the SLIIB RNA target. Enhanced activity on the SLIIB RNA target was also observed with the Rev-eTat fusion protein in both mouse and quail cells. We therefore conclude that the species tropism of eTat again primarily reflects speciesspecific differences in the efficiency of the interaction between eTat and EIAV TAR rather than differences in eTat activation potential.
HIV-1 Tat and eTat interact with the same cellular cofactor. The markedly different RNA sequence specificities and primary sequences of the Tat proteins of HIV-1 and EIAV, when combined with their dissimilar species tropism, could be viewed as inconsistent with the hypothesis that these distantly related lentivirus regulatory proteins interact with the same cellular cofactor. However, the observation that these proteins can each trans activate the HIV-1 LTR by >100-fold when targeted to the introduced SLIIB target by fusion to Rev (Table 2) could also indicate similar mechanisms of action.
To address whether HIV-1 Tat and eTat indeed interact with the same cofactor in human cells, we examined whether Tat and eTat could inhibit the activity of Tat on HIV-1 TAR, Tat/Rev on SLIIB, or Rev/eTat on SLIIB (Fig. 6 ) in transfected HeLa cells. Specificity controls were provided by the effector domain-minus K41A mutant of Tat and the similar R43G mutant of eTat. As shown in Fig. 6 , both Tat and eTat, but not the K41A or R43G derivative, were able to very effectively inhibit the activity of either Tat-Rev and ReveTat on the SLIIB target. Remarkably, eTat, which is not active on the HIV-1 TAR element ( Fig. 5 . In particular, these data support the following hypotheses.
(i) The interaction of Tat with an essential cellular cofactor is independent of TAR binding. This hypothesis is supported by two observations. First, the Tat-Rev fusion protein is fully functional when targeted to the heterologous SLIIB RNA target sequence, and this activity is not affected by mutation of the Tat basic domain (Fig. 4) . Second, both Tat and a Tat mutant (ARK) lacking a functional basic domain are able to effectively squelch the activity of Tat-Rev via the SLIIB target sequence (Table 1) . In contrast, the activity of Tat-Rev on the SLIIB RNA target and the ability of Tat to inhibit this activity are both dependent on the integrity of the Tat cysteine and core motifs and, to a lesser extent, the N-terminal domain. These observations confirm and extend previously published results obtained by using Tat-MS2 coat protein fusions and an HIV-1 LTR construct containing the MS2 operator RNA in place of TAR (9, 42) or by using a GAL4-Tat fusion protein targeted to a GAL4 DNA binding site introduced into the HIV-1 LTR U3 region (44) . Overall, these data demonstrate that the arginine-rich RNA binding domain of Tat plays at most a minor role in mediating the interaction of Tat with a cellular cofactor(s) and further suggest that the Tat cofactor binding domain is coincident with the first -48 amino acids of Tat, including, in particular, the Tat core and cysteine motifs (8, 13, 44) .
(ii) The interaction of Tat with a cellular cofactor is a prerequisite for TAR binding in vivo. Several groups have demonstrated that the Tat basic domain is not only necessary but also fully sufficient for TAR binding in vitro (6, 40, 49) . In particular, neither the Tat core motif nor the Tat cysteine motif appears to play any detectable role in mediating this interaction in vitro (22) . Tat mutants lacking a functional cysteine or core motif, such as C22S, C37S, and K41A, should therefore compete effectively with wild-type Tat for TAR binding in vivo. However, none of these three inactive mutants proved capable of exerting any inhibitory effect on Tat in transfected cells (Table 1 ). In contrast, Rev, which could be viewed as a Tat-Rev derivative lacking a functional effector domain, was able to markedly inhibit Tat-Rev function via SLIIB by competing for SLIIB RNA binding. It should be emphasized that the C22S, C37S, and K41A Tat proteins are all fully stable in vivo and also display an apparently wild-type subcellular localization (Fig. 3) (25, 41, 47) . The simplest interpretation of this result is therefore that the cofactor binding domain of Tat plays a critical role in mediating TAR binding in vivo.
(iii) Tat may directly interact with only a single cellular cofactor. As shown in Fig. 1 , Tat appears to contain at least three motifs that are essential for in vivo function. The basic domain's sole purpose lies in mediating the interaction of Tat with TAR, while both the cysteine and core motifs are required for Tat effector function. The question then becomes whether these motifs bind one or more cellular cofactors. Clearly, genetic experiments such as those described in this report cannot distinguish between binding of a single polypeptide, binding of a preformed multiprotein complex, or the highly cooperative binding of two or more cofactors to Tat. However, these data do not appear consistent with the hypothesis that Tat binds two or more cellular cofactors independently. For example, if the core and cysteine motifs each bound a distinct cellular cofactor that was independently required for activation, then one would predict that mutation of one motif would leave the other free to bind, and hence sequester, the other cellular cofactor. However, none of these point mutants proved able to exert such a squelching phenotype (Table 1) . Further, if a distinct sequence located within either the Tat core or cysteine motif was involved in effector function while a second was involved in recruiting a cofactor required for TAR binding, we would then predict that mutation of the former would give a protein that could compete for TAR binding, while mutation of the latter would give a protein that was active when fused to Rev, i.e., the phenotype seen with ARK. However, all core and cysteine motif mutants proved inactive in the Rev fusion context. The simplest hypothesis to explain these observations is therefore that the N-terminal -48 amino acids of Tat, including, in particular, the cysteine and core motifs, likely bind a single cellular cofactor.
(iv) Tat does not contain a transcription activation domain per se. Several classes of transcription activation domains have been defined. Of these, the most intensively studied is clearly the acidic activation motif first defined in the yeast protein GAL4 and seen in a particularly active form in the herpes simplex virus trans activator VP16 (32, 37) . Rappaport et al. (39) (2) .
(vi) Lentivirus Tat proteins interact with the same cellular cofactor. Among lentivirus Tat proteins, that of EIAV is the most dissimilar to that of HIV-1. The eTat protein is unique among Tat proteins in lacking a cysteine motif and is also unusual in that it shows no ability to trans activate the HIV-1 LTR (8, 13) . Remarkably, however, the eTat protein proved as effective as HIV-1 Tat in trans activating the HIV-1 LTR when both were targeted to the SLIIB RNA sequence by fusion to Rev ( Table 1 ). The equivalent, -100-fold trans activation seen with these two distinct Tat fusion proteins suggested that they might be recruiting the same transcription factor to the SLIIB RNA target. To (9) nevertheless also proposed that HIV-1 Tat and eTat interact with the same cellular cofactor prior to binding their homologous TAR element (Fig. 5) .
(vii) The cellular cofactor modulates the RNA sequence specificity of the Tat-cofactor complex. The TAR elements of the lentiviruses HIV-1 and EIAV are quite distinct (Fig. 2) . In particular, the EIAV TAR element clearly lacks any equivalent of the pyrimidine-rich bulge and conserved hexanucleotide loop that are critical for HIV-1 TAR function in vivo (10) . It is, therefore, not surprising that HIV-1 Tat is inactive on the EIAV TAR element and vice versa (Table 2) . However, the evidence presented above clearly indicates that the cellular cofactors recruited by Tat and eTat are the same, at least in human cells. We have argued that Tat interacts with a single cofactor and that this cofactor affects the efficiency of the Tat-TAR interaction. This view implies that the same cellular cofactor must be involved in mediating the interaction of both HIV-1 Tat and eTat with their respective, highly divergent, TAR elements. It is, therefore, not surprising that these interactions are not equivalently efficient in cells from different species ( Table 2 ). The human cofactor is, according to this hypothesis, highly effective at mediating the Tat-TAR interaction of the human virus HIV-1 but is far less competent to mediate the Tat-TAR interaction of the equine virus EIAV. The high activity of eTat in equine and canine cells (8, 13) implies that these species express an analogous protein that can effectively mediate this latter binding event. The equivalent protein expressed by mouse and quail cells, in contrast, is not proficient at mediating either of these Tat-TAR interactions but could, presumably, be effective on yet a third RNA sequence.
Of interest, the observation that the HIV-1 and EIAV Tat proteins can work effectively in a range of species, including nonmammalian cells, when targeted to a heterologous RNA binding domain (Table 2) indicates that the Tat cofactor has been conserved since the evolutionary divergence of mammals and birds and has also retained the structural features that allow it to interact with Tat. However, it also appears that the RNA sequence specificity of this cofactor has evolved significantly over time, thus generating the species tropisms that are now characteristic of the various lentivirus Tat proteins.
A model for the temporal assembly of a ternary complex on TAR. In this report, we have presented a genetic analysis of the role of the cellular cofactor in the mechanism of action of Tat. These data, in combination with recent observations from other groups (2, 9, 42, 46) , have suggested a specific model for the genesis of the Tat transcription activation complex (Fig. 5) . The primary, and most novel, feature of this model is that neither Tat nor the cellular Tat cofactor binds TAR alone in vivo. Instead, we propose that these proteins must first form a protein complex. This complex then binds to TAR with a sequence specificity that is determined both by Tat and by the cellular cofactor (Fig. 5) . This hypothesis is therefore inconsistent with the contention, based entirely on in vitro analysis, that Tat alone can bind to TAR in vivo.
Although the binding of TAR by the Tat basic motif in vitro occurs with high affinity, it displays a relatively low level of specificity. Thus, Tat proteins in which the basic motif has been substituted by other natural or artificial stretches of basic amino acids have been reported to retain full in vivo activity (6, 45) , while the ability of the basic domain of Tat to selectively bind TAR appears to be specified by a single arginine residue within the basic motif (7) . Indeed, the amino acid arginine itself seems to retain much of the same RNA specificity (38) . It has therefore seemed improbable that the sequence information present in the basic motif of Tat could alone be sufficient to direct the specific binding of Tat to TAR under in vivo conditions. The hypothesis that a cellular cofactor might be involved in mediating the Tat-TAR interaction was first suggested by the observation that the ability of a TAR RNA decoy to sequester the Tat protein in vivo, and hence inhibit HIV-1 LTR trans activation, was critically dependent on the integrity of terminal loop RNA sequences that have no effect on Tat binding in vitro (46) . As noted above, the data presented in this report strongly support the proposal that the interaction of Tat with a cellular cofactor is, in fact, an essential prerequisite for TAR binding in vivo.
The TAR element cannot bind an essential cellular cofactor distinct from the one that binds to Tat, because it would then be impossible to functionally substitute a heterologous RNA target sequence for TAR. Given, then, that the cellular cofactors that bind Tat and TAR are one and the same, what is the evidence that the cofactor does not bind TAR alone? The most compelling evidence for this hypothesis derives from the observation that the interaction of TAR with a cellular cofactor is necessary but not sufficient to direct Tat to TAR. The evidence for necessity includes the observation that TAR sequences that are not directly involved in binding to Tat are nevertheless required for TAR function in vivo (14, 40) as well as the finding that the species origin of the Tat VOL. 67, 1993 on July 6, 2017 by guest http://jvi.asm.org/ Downloaded from cofactor markedly affects the level of trans activation obtained with a particular TAR element ( Table 2 ). The evidence that the TAR-cofactor interaction is not sufficient to recruit Tat to TAR derives from the finding that the Tat basic domain is critical for TAR binding, but not effector function, in vivo (Fig. 4) (42, 44) and that complexes of the same cellular Tat cofactor with either HIV-1 Tat or eTat display entirely different TAR RNA sequence specificities in vivo (Table 2) . Indeed, the data presented in this report are fully consistent with the hypothesis, first suggested by Carroll et al. (9) , that the entire purpose of Tat is simply to recruit the apparently ubiquitous cellular transcription factor referred to here as the Tat cofactor to a novel, viral RNA target sequence and to thereby activate viral LTR-specific gene expression. Tat could therefore be viewed more as a trans specifier of a preexisting cellular transcription factor than as a transcriptional trans activator in its own right.
An important prediction of the model presented in Fig. S is that the cellular Tat cofactor is unlikely to bind TAR with significant affinity in the absence of Tat. Efforts to define the Tat cofactor on the basis of its ability to bind TAR in vitro may therefore be doomed to failure. Instead, our data would suggest that it is the affinity of the cofactor for Tat itself that should provide the best biochemical or genetic tool for the identification of this interesting cellular regulatory protein.
